1) Strong Orders and Backlog Growth - Orders increased by 11% year-over-year, with a record backlog of $23.9 billion, up $2.6 billion YoY. - Book-to-bill ratio stood at 1.15x, indicating strong demand across all segments. - The growth was broad-based, with significant contributions from ultrasound, MR, CT, and patient monitoring.

2) Financial Performance Highlights - Revenue for Q2 2026 was $5.3 billion, reflecting 3.5% organic growth YoY. - Product revenues grew by 4.7%, while service revenues saw a 7.7% increase. - Adjusted EBIT was $750 million, with an adjusted EBIT margin of 14.2%, down 40 basis points YoY. - Adjusted EPS reached $1.13, up 6.6% YoY, benefiting from tariff refunds and a lower tax rate.

3) Challenges in Patient Care Solutions - Patient Care Solutions (PCS) experienced a revenue decline of 13.5%, attributed to operational fulfillment challenges and supply chain issues. - Despite these challenges, PCS saw strong orders growth in monitoring, indicating potential for recovery. - A strategic review of PCS is underway to explore options for maximizing long-term growth, including potential sale or restructuring.

4) Innovation and Product Pipeline - The company is focused on launching new AI-enabled products, with several innovations expected to drive growth in the second half of 2026 and beyond. - Photonova Spectra, a photon-counting CT platform, is anticipated to enhance market opportunities post CE marking. - The pharmaceutical diagnostics segment reported strong growth of 14.6%, driven by increased adoption of disease-specific tracers and the Flyrcado ramp.

5) Guidance and Outlook - GE Healthcare maintains its full-year guidance of 3% to 4% organic sales growth and adjusted EBIT margin expansion of 10 to 40 basis points. - Adjusted EPS guidance remains at $4.80 to $5.00, with expectations for low double-digit growth YoY. - The call did not provide specific updates on the ongoing CFO search or detailed impacts from potential generic competition in the contrast media market.

Bottom line: GE Healthcare demonstrated robust order growth and a solid financial performance in Q2 2026, despite challenges in the PCS segment. The company's focus on innovation and strategic initiatives positions it well for continued growth, making it a compelling investment for shareholders.